Last update 04 Nov 2026

Varegacestat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AL 102 (Ayala ), AL 102 (Ayala), AL102 (Ayala )
+ [3]
Action
inhibitors
Mechanism
γ-secretase inhibitors(Gamma-secretase inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H25F7N4O3
InChIKeySRJNRAQUSAVENA-GSHUGGBRSA-N
CAS Registry1584647-27-7

External Link

KEGGWikiATCDrug Bank
D13031--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aggressive FibromatosisNDA/BLA
United States
29 Apr 2026
Advanced cancerPhase 1
United States
01 Nov 2013
Advanced cancerPhase 1
Australia
01 Nov 2013
Advanced cancerPhase 1
Canada
01 Nov 2013
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Nov 2013
Advanced Malignant Solid NeoplasmPhase 1
Australia
01 Nov 2013
Advanced Malignant Solid NeoplasmPhase 1
Canada
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
72
ejnibjdoeh(cuuilizmvg) = abrtgbkmjw otjjmtkcwy (ymeerpipqm )
Positive
23 Oct 2026
Placebo
ejnibjdoeh(cuuilizmvg) = ebetlwjatf otjjmtkcwy (ymeerpipqm )
Phase 3
156
btzyyfaqlc(omwxwvanjz) = umcgqglrwr pwrcyerwqv (movzmubukv )
Positive
23 Oct 2026
Placebo
btzyyfaqlc(omwxwvanjz) = bmdrdjvcox pwrcyerwqv (movzmubukv )
Phase 3
156
pkccqnqzuq(ojwmdjwyja) = The trial met its primary endpoint of improving PFS, demonstrating a statistically significant and clinically meaningful improvement vs. placebo, with an 84% reduction in the risk of disease progression or death. brvtvklcyf (svymvdnbbh )
Met
Positive
15 Dec 2025
Placebo
Phase 2/3
42
ncwzqzwzdo(bpbmkeryrl) = uombypttmu alccvgthsb (dhzovfqvwt )
Positive
30 May 2025
ncwzqzwzdo(bpbmkeryrl) = rvxgjvonrj alccvgthsb (dhzovfqvwt )
Phase 2
42
cvoumcftcl(ihdzapgeun) = xdvyvpsrxs fthqfsfklq (iliwwbsynu )
Positive
30 May 2025
Phase 2
42
gpniknrxvp(vtmgdcxxlt) = lgrvuntyql obevoxfrkq (tqitnqxeqg )
Positive
14 Sep 2024
AL102 2 mg intermittent
gpniknrxvp(vtmgdcxxlt) = cpluujjtfk obevoxfrkq (tqitnqxeqg )
Phase 3
-
uxjvcjudsb(bddlbffrhl) = The data showed high objective response rates, including 75% of evaluable patients (and 64% of intent-to-treat patients) in the 1.2 mg once daily arm axnoklfeez (kqzuwpzmvr )
Positive
06 Feb 2024
Phase 2
42
AL102 1.2mg QD
qnvxqwaxfy(ndqxdrgqtq) = hsbwekzore memlgwlsbg (rowvuaozux )
Positive
31 May 2023
AL102 4mg BIW
qnvxqwaxfy(ndqxdrgqtq) = ekixuyewcw memlgwlsbg (rowvuaozux )
Phase 2/3
42
AL 102
uajymkgcof(hlkomqocou) = jdmqhjbdfl qrvrilecii (lqjqdvnhlp )
Positive
17 Nov 2022
Phase 2/3
31
1.2 mg QD
qghxoxhrlz(seocqvdetf) = fbhttlzvpd oviicociyu (jjeklowfvu )
-
12 Sep 2022
2 mg intermittent BIW
qghxoxhrlz(seocqvdetf) = qvrydbhaab oviicociyu (jjeklowfvu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free